p53 and Bcl-2 protein expression and its relationship with prognosis in small-cell lung cancer

Clinical Lung Cancer

Volumn 4, Issue 5, 2003, Pages 298-302

  Zereu, Manuela ^a   Fonseca Vinholes, Jeferson Jose ^a   Galeano Zettler, Cláudio ^b  

^a Santa Casa Complexo Hospitalar   (Brazil)

^b Federal Foundation School of Medical Sciences   (Brazil)

Author keywords

Benzo(a)pyrene; Extensive stage disease; Immunohistochemistry; Limited stage disease; Molecular markers; Prognostic factors; Tumor suppressor gene

Indexed keywords

BIOCHEMICAL MARKER; MONOCLONAL ANTIBODY; ONCOPROTEIN; PARAFFIN; PROTEIN BCL 2; PROTEIN P53;

ADULT; AGE; AMINO TERMINAL SEQUENCE; ARTICLE; BODY WEIGHT; BRONCHUS BIOPSY; CANCER STAGING; CANCER SURVIVAL; CLINICAL STUDY; CONTROLLED STUDY; CORRELATION ANALYSIS; FEMALE; HEALTH STATUS; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; LUNG SMALL CELL CANCER; MAJOR CLINICAL STUDY; MALE; PROGNOSIS; PROTEIN EXPRESSION; RETROSPECTIVE STUDY; SEX DIFFERENCE; WEIGHT REDUCTION; WORLD HEALTH ORGANIZATION;

EID: 0037847606     PISSN: 15257304     EISSN: None     Source Type: Journal    
DOI: 10.3816/CLC.2003.n.010     Document Type: Article

References (43)

1. Wistuba II, Gazdar AF, Minna JD. Molecular genetics of small cell lung carcinoma. Semin Oncol 2001; 28(suppl 4):3-13.
2. Murren J. Small cell lung cancer. In: DeVita VT Jr, Hellman S, Rosenberg SA, eds. Cancer: Principles and Practice of Oncology. Philadelphia, PA: Lippincott Williams & Wilkins; 2001:983-1018.
3. Moreira J. Carcinoma Brônquico. In: Silva LC, ed. Condutas em Pneumologia. Rio de Janeiro, Brazil: Revinter; 2001:553-570.
4. Johnson DH. Small cell lung cancer in the elderly patient. Semin Oncol 1997; 24:484-491.
5. Shepherd FA. Alternatives to chemotherapy and radiotherapy in the treatment of small cell lung cancer. Semin Oncol 2001; 28(suppl 4):30-37.
6. Curran WJ. Combined-modality therapy for limited-stage small cell lung cancer. Semin Oncol 2001; 28(suppl 4):14-22.
7. Micke P, Faldum A, Metz T, et al. Staging small cell lung cancer: Veterans Administration Lung Study Group versus International Association for the Study of Lung Cancer - what limits disease? Lung Cancer 2002; 37:271-276.
8. Zelen M. Keynote address on biostatistics and data retrieval. Cancer Chemother Rep 1973; 4:31-42.
9. Argiris A, Murren JR. Staging and clinical prognostic factors for small cell lung cancer. Cancer J 2001; 7:437-447.
10. Deppermann K. Influence of age and comorbidities on the chemotherapeutic management of lung cancer. Lung Cancer 2001; 33(suppl 1):S115-S120.
11. Yip D, Harper PG. Predictive and prognostic factors in small cell lung cancer: current status. Lung Cancer 2000; 28:173-185.
12. Albain KS, Crowley JJ, Le Blanc M, et al. Determinants of improved outcome in small-cell lung cancer: an analysis of the 2580 patients of the Southwest Oncology Group data base. J Clin Oncol 1990; 8:1563-1574.
13. Salgia R, Skarin AT. Molecular abnormalities in lung cancer. J Clin Oncol 1998; 16:1207-1217.
14. Sekido Y. Molecular biology of lung cancer. In: DeVita VT Jr, Hellman S, Rosenberg SA, eds. Cancer: Principles and Practice of Oncology Philadelphia, PA: Lippincott Williams & Wilkins; 2001:849-857.
15. Carbone DP. The biology of lung cancer. Semin Oncol 1997; 24:388-401.
16. Dursun BA, Memis L, Bayrz H, et al. Clinical importance of correlations between p53 immunoreactivity and clinicopathological parameters in lung carcinoma. Pathol Oncol Res 1999; 5:285-290.
17. Ziegler A, Luedke GH, Fabbro D, et al. Induction of apoptosis in small-cell lung cancer cells by an antisense oligodeoxynucleotide targeting the Bcl-2 coding sequence. J Natl Cancer Inst 1997; 89:1027-1036.
18. Takayama K, Ogata K, Nakanishi Y, et al. Bcl-2 expression as a predictor of chemosensitivity and survival in small cell lung cancer. Cancer J Sci Am 1996; 2:212.
19. Maitra A, Amirkhan RH, Saboorian MH, et al. Survival in small cell lung carcinoma is independent of Bcl-2 expression. Hum Pathol 1999; 30:712-717.
20. Stefanaki K, Rontogiannis D, Vamvouka C, et al. Immunohistochemical detection of bcl2, p53, mdm2 and p21/waf1 proteins in small-cell lung carcinomas. Anticancer Res 1998; 18:1689-1695.
21. Ettinger DS. New drugs for chemotherapy-naive patients with extensive-disease small cell lung cancer. Semin Oncol 2001; 28(suppl 4):27-29.
22. Rodriguez-Salas N, Palacios J, Moreno G, et al. Correlation of p53 oncoprotein expression with chemotherapy response in small cell lung carcinomas. Lung Cancer 2001; 34:67-74.
23. Morris D. Limited stage small cell lung cancer. In: Detterbeck FC, Rivera MP, Socinski MA, et al, eds. Diagnosis and Treatment of Lung Cancer: An Evidence-Based Guide for the Practicing Clinician. Philadelphia PA: WB Saunders; 2001:341-359.
24. Radzikowska E, Glatz P, Roszkowski K. Lung cancer in women: age, smoking, performance status, stage, initial treatment and survival. Population-based study of 20 561 cases. Ann Oncol 2002; 13: 1887-1093.
25. Skarin AT, Herbst RS, Leong TL. Lung cancer in patients under age 40. Lung Cancer 2001; 32:255-264.
26. Lassen U, Osterlind K, Hansen M, et al. Long-term survival in small-cell lung cancer: posttreatment characteristics in patients surviving 5 to 18+ years an analysis of 1,714 consecutive patients. J Clin Oncol 1995; 13:1215-1220.
27. Jacoulet P, Depierre A, Moro D, et al. Long-term survivors of small-cell lung cancer (SCLC): a French multicenter study. Groupe d'Oncologie de Langue Francaise. Ann Oncol 1997; 8:1009-1014.
28. Janssen-Heijnen ML, Schipper RM, Klinkhamer PJJ, et al. Improvement and plateau in survival of small-cell lung cancer since 1975: a population-based study. Ann Oncol 1998; 9:543-547.
29. Jennens R, Rosenthal MA, Mitchell P, et al. Outcome of patients admitted to the intensive care unit with newly diagnosed small cell lung cancer. Lung Cancer 2002; 38:291-296.
30. Paesmans M, Sculier JP, Lecomte J, et al. Prognostic factors for patients with small cell lung carcinoma: analysis of a series of 763 patients included in 4 consecutive prospective trials with a minimum follow-up of 5 years. Cancer 2000; 89:523-533.
31. Detterbeck F. Clinical Presentation and Diagnosis. In: Detterbeck FC, Rivera MP, Socinski MA, et al, eds. Diagnosis and Treatment of Lung Concer: An Evidence-Based Guide for the Practicing Clinician. Philadelphia, PA: WB Saunders; 2001:45-72.
32. Jiang SX, Sato Y, Kuwao S, et al. Expression of bcl-2 oncogene protein is prevalent in small cell lung carcinomas. J Pathol 1995; 177:135-138.
33. Higashiyama M, Doi O, Kodama K, et al. Bcl-2 oncoprotein expression is increased especially in the portion of small cell carcinoma within the combined type of small cell lung cancer. Tumour Biol 1996; 17:341-344.
34. Dingemans AM, Witlox MA, Stallaert RA, et al. Expression of DNA topoisomerase II alpha and topoisomerase II beta genes predicts survival and response to chemotherapy in patients with small cell lung cancer. Clin Cancer Res 1999; 5:2048-2058.
35. Gemba K, Ueoka H, Kiura K, et al. Immunohistochemical detection of mutant p53 protein in small-cell lung cancer: relationship to treatment outcome. Lung Cancer 2000; 29:23-31.
36. Orfanidou D, Kalomenidis J, Rasidakis J, et al. Immunohistochemical detection of p53 protein in neoplastic, preneoplastic and normal bronchial mucosa specimens obtained during diagnostic bronchoscopy. Oncol Rep 1998; 5:763-769.
37. Ben-Ezra JM, Kornstein MJ, Grimes MM, et al. Small cell carcinomas of the lung express the Bcl-2 protein. Am J Pathol 1994; 145:1036-1040.
38. Koty P, Zhang H, Franklin WA, et al. In vivo expression of p53 and bcl-2 and their role in programmed cell death in premalignant and malignant lung lesions. Lung Cancer 2002; 35:155-163.
39. Cottin V, Arpin D, Lasset C, et al. Small-cell lung cancer: patients included in clinical trials are not representative of the patient population as a whole. Ann Oncol 1999; 10:809-815.
40. Jara C, Gomez-Aldaravi JL, Fernandez A, et al. Small-cell lung cancer in the elderly: is age of patient a relevant factor? Acta Oncol 1999; 38:781-786.
41. Lesbitasy MP, Hédelin G, Purohit A, et al. Progress in the management and outcome of small cell lung cancer in a French region from 1981 to 1994. Br J Cancer 2001; 85:808-815.
42. Sozzi G. Molecular biology of lung cancer. Eur J Cancer 2001; 37(suppl 7):S63-S73.
43. McLaren R, Kuzu I, Dinnill M, et al. The relationship of p53 immunostaining to survival in carcinoma of the lung. Br J Cancer 1992; 66:735-738.